Allergy Shots: Do They Work? The Honest Evidence-Based Verdict
Allergy shots work — a Cochrane review of 51 randomized trials found they significantly reduce rhinitis symptoms and medication use. But the skeptic's case deserves hearing: 10-15% are non-responders, dropout rates reach 50-70%, and placebo effects complicate self-assessment. Shots work best for moderate-to-severe allergic rhinitis with IgE-confirmed sensitization to fewer than 5 allergens in committed patients. The verdict: for the right patient, yes — but completion is the rate-limiting factor.
7 peer-reviewed sources
Yes, allergy shots work — 51 randomized controlled trials confirm significant symptom and medication reduction. But they work best for specific patients, and the main reason they fail is early dropout before completing the recommended course.
Evaluating Both Sides: Why Allergy Shot Skepticism Deserves a Real Answer
The skeptic's version of this question — 'allergy shots, do they actually work?' — deserves a more complete answer than a simple 'yes, look at the studies.' If you are skeptical after hearing mixed experiences from friends, seeing someone's treatment 'fail,' or having concerns about years of weekly injections, this page is for you.
Here is the honest picture. The strongest evidence in allergy medicine firmly supports allergy shots: a Cochrane review of 51 randomized controlled trials in nearly 2,900 patients found SCIT significantly reduces both symptom scores and medication use compared to placebo. Multiple independent systematic reviews replicate these results. WHO, AAAAI, EAACI, and WAO all endorse SCIT as the only disease-modifying treatment for IgE-mediated allergy.
At the same time, the evidence contains real limitations that are often underemphasized. Ten to fifteen percent of patients do not respond despite optimal dosing and adequate duration. A 20 to 40% placebo response rate in allergy trials makes it genuinely difficult for individual patients to assess whether their improvement is real or expected. And the single most common reason allergy shots 'don't work' is that patients stop before treatment is complete — real-world data show only 23% of SCIT patients complete the recommended 3-year minimum.
Before starting treatment, confirming IgE-mediated sensitization to relevant allergens through allergy testing is essential — at-home options like Curex provide comprehensive IgE panels covering 40 or more allergens, giving your allergist the diagnostic clarity needed to determine whether allergy shots are the right choice for you.
Allergy shots work for most patients with IgE-confirmed sensitization who commit to completing treatment. The main reasons they 'don't work' are choosing the wrong patients and not completing the full course.
Why Allergy Shots Work When Completed: The Immune Science
When someone questions whether allergy shots work, it helps to understand precisely what the mechanism is — because the biology is unambiguous, even when clinical trial results show variation. SCIT works by inducing immune tolerance through a cascade of molecular changes that are well characterized and reproducible.
Allergen Delivered to Immune Tissue
Subcutaneous injection deposits allergen extract into the dermis, where dendritic cells capture allergen proteins and begin the process of antigen presentation that will ultimately produce tolerance rather than allergic attack.
Regulatory T Cells Are Induced
Dendritic cells in regional lymph nodes present allergen in a tolerogenic context, inducing FOXP3+ regulatory T cells (Tregs) and IL-10-producing Tr1 cells. These Tregs specifically suppress the allergen-driven Th2 inflammatory cascade — the root cause of allergy symptoms.
Blocking Antibodies Replace Reaction Antibodies
B cells class-switch from producing IgE (which triggers mast cells and basophils to release histamine) to IgG4 blocking antibodies that rise 10- to 100-fold. These blocking antibodies compete with IgE for allergen binding, intercepting the allergen before it can trigger symptoms.
Mast Cell Reactivity Diminishes
Over months to years of treatment, mast cells and basophils in allergic tissues become progressively less reactive — their threshold for degranulation rises, meaning the same allergen exposure that used to cause sneezing and swollen eyes no longer triggers a significant response.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
The Evidence: What the Clinical Trials Actually Show
The evidence for allergy shots does not depend on any single study or any single allergen. Multiple independent research groups using different allergens, populations, and outcome measures have reached the same conclusion: SCIT significantly outperforms placebo for allergic rhinitis and allergic asthma. The effect sizes are moderate-to-large by clinical standards and are accompanied by real-world data confirming clinical meaningfulness.
Success Rate by Duration
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSCIT vs. Alternatives: The Verdict With Context
Whether allergy shots work better than the alternatives depends on what you are comparing and over what time horizon. For short-term symptom control, antihistamines and nasal steroids are faster and cheaper. For long-term disease modification — actually changing the immune response so treatment can eventually stop — only immunotherapy achieves this. The choice of modality (shots vs. drops) matters less than whether the patient commits to completing the full course.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT, Curex)Best | Strongest evidence base (51+ RCTs); disease-modifying; 85-90% improvement in compliant patients | 3-5 years active treatment | $3,000-15,000 | Weekly self-administered shots at home with Curex in build-up; brief self-observation after each dose; removing the clinic trip lowers what was the highest adherence barrier of any IT modality | 0.1% systemic reaction risk per injection; at home with Curex the first dose and dose changes are supervised live over Zoom, the serum is sterile-compounded to USP <797>, and a prescribed epinephrine auto-injector is confirmed on hand |
Sublingual Drops (SLIT) | Comparable efficacy to SCIT; disease-modifying; daily self-administration eliminates the weekly clinic visit barrier | 3-5 years daily drops | $2,340-3,000 | Daily at-home drops; no injections, no clinic waits; removes dominant adherence barrier | Markedly safer than SCIT; no confirmed fatalities in published literature |
Daily Antihistamines | Moderate symptom control; no disease modification; does not 'work' in the sense of changing the underlying allergy | Indefinite ongoing use | $600-2,500 | Daily pill; OTC available; rapid onset; no appointments | Well-tolerated; no immune effects |
Nasal Corticosteroids | Best single-agent symptom control matching SCIT short-term; zero disease modification | Indefinite daily use during season or year-round | $500-3,000 | Daily nasal spray; prescription or OTC; no immune effects | Well-tolerated; no systemic immune suppression at nasal doses |
- Efficacy
- Strongest evidence base (51+ RCTs); disease-modifying; 85-90% improvement in compliant patients
- Duration
- 3-5 years active treatment
- Cost (5yr)
- $3,000-15,000
- Convenience
- Weekly self-administered shots at home with Curex in build-up; brief self-observation after each dose; removing the clinic trip lowers what was the highest adherence barrier of any IT modality
- Safety
- 0.1% systemic reaction risk per injection; at home with Curex the first dose and dose changes are supervised live over Zoom, the serum is sterile-compounded to USP <797>, and a prescribed epinephrine auto-injector is confirmed on hand
- Efficacy
- Comparable efficacy to SCIT; disease-modifying; daily self-administration eliminates the weekly clinic visit barrier
- Duration
- 3-5 years daily drops
- Cost (5yr)
- $2,340-3,000
- Convenience
- Daily at-home drops; no injections, no clinic waits; removes dominant adherence barrier
- Safety
- Markedly safer than SCIT; no confirmed fatalities in published literature
- Efficacy
- Moderate symptom control; no disease modification; does not 'work' in the sense of changing the underlying allergy
- Duration
- Indefinite ongoing use
- Cost (5yr)
- $600-2,500
- Convenience
- Daily pill; OTC available; rapid onset; no appointments
- Safety
- Well-tolerated; no immune effects
- Efficacy
- Best single-agent symptom control matching SCIT short-term; zero disease modification
- Duration
- Indefinite daily use during season or year-round
- Cost (5yr)
- $500-3,000
- Convenience
- Daily nasal spray; prescription or OTC; no immune effects
- Safety
- Well-tolerated; no systemic immune suppression at nasal doses
For skeptics wary of the 3-to-5-year clinic commitment, Curex now delivers the shot route itself as an at-home allergy shot kit (SCIT) — the same evidence-backed immunotherapy, prescribed and overseen by board-certified allergists, for $129/month all-inclusive. You give one weekly shot at home from a personalized serum sterile-compounded to USP <797>, and your first dose and every dose change are supervised live over Zoom after a prescribed epinephrine auto-injector is confirmed on hand.
See if at-home shots are right for youFrequently asked questions
What is the success rate of allergy shots?
Among patients who complete the full recommended course, approximately 85 to 90% report significant improvement in allergic symptoms. The Cochrane review by Calderon et al. (2007), synthesizing 51 randomized controlled trials, found a standardized mean difference of -0.73 for symptom scores and -0.57 for medication use — classified as a moderate-to-large clinical effect. In real-world studies, however, only about 23% of SCIT patients actually complete the minimum 3-year duration (Kiel et al., JACI 2013). This adherence gap is why population-level effectiveness is lower than trial-protocol efficacy. The number needed to treat to achieve meaningful improvement beyond medication alone is approximately 3 patients.
Who does NOT benefit from allergy shots?
Allergy shots are unlikely to work for several patient categories. Patients with non-allergic rhinitis — where no IgE sensitization underlies the symptoms — will not respond because there are no allergen-specific antibodies for SCIT to modify. Those with mild, easily controlled symptoms may not benefit enough to justify the treatment burden. Patients allergic to more than 5 to 10 unrelated allergens face dilution problems in multi-allergen vials that reduce per-allergen dosing below therapeutic thresholds. Poor compliance history is a strong predictor of treatment failure. And 10 to 15% of otherwise appropriate candidates are simply non-responders, possibly due to non-allergic components of their disease or immunologic variability.
Why do allergy shots not work for some people?
The most common reason allergy shots do not work is incomplete treatment — stopping before completing the recommended 3- to 5-year course. Real-world data from Kiel et al. show the median SCIT persistence is only 1.7 years, well below the minimum needed for durable benefit. Beyond adherence, other reasons include: non-allergic rhinitis misdiagnosed as allergic; polysensitization with inadequate per-allergen dosing in multi-allergen vials; subtherapeutic maintenance dosing; failure to identify and treat all relevant allergens; and the 10 to 15% true non-responder rate. A significant placebo response in allergy trials (20 to 40%) also means some patients who improve on shots would have improved without them.
How long until allergy shots start working?
Most patients begin noticing symptom improvement within 3 to 6 months of starting allergy shots, typically coinciding with reaching the maintenance dose during or near the end of the build-up phase. The AAAAI/ACAAI Practice Parameter states that clinical improvement usually is observed within 1 year after a patient reaches maintenance dosing. Some patients require 12 or more months before meaningful benefit becomes apparent, particularly those with more complex sensitization patterns. If no improvement is evident after 1 year on a proper maintenance dose with optimal allergen selection, the guidelines recommend considering discontinuation. The slow onset — compared to antihistamines — is one of the main reasons patients stop early before reaching full benefit.
Do allergy shots work for everyone with seasonal allergies?
Allergy shots work for most — but not all — people with IgE-confirmed seasonal allergies. The prerequisite is demonstrable specific IgE sensitization to clinically relevant seasonal allergens, confirmed by skin prick testing (wheal 3 mm or more above negative control) or specific IgE blood testing (0.35 kU/L or above). Among patients who meet this criterion and complete treatment, 85 to 90% achieve significant improvement. However, patients whose 'seasonal allergies' include a non-allergic rhinitis component — triggered by irritants, temperature changes, or autonomic dysfunction — will not have that component resolved by SCIT, even if the IgE-mediated portion improves substantially.
Are allergy shots worth the time commitment?
Cost-effectiveness analyses consistently show that allergy shots become economically superior to ongoing medication use after approximately 3 years, with modeling studies projecting net savings of $6,000 to $12,000 per decade. Hankin et al. (JACI 2013) found that allergy immunotherapy reduced total allergy-related healthcare costs by 33% in a matched Medicaid cohort. Beyond economics, 80% of SCIT completers report they would recommend treatment to others, and 75% rate their improvement as significant or very significant. The time commitment — 36 to 130 office visits over 3 to 5 years — is substantial, but patients who complete it overwhelmingly view it as worthwhile compared to indefinite medication dependence.
Can allergy shots stop working after they initially worked?
It is possible for allergy shot benefits to wane after initially providing relief, particularly if treatment is stopped before completing the full recommended course. Approximately 25% of patients experience clinically significant relapse within 3 years of stopping, most commonly those who stopped before the 5-year mark and those with polysensitization. Benefits can also appear diminished if new allergen sensitivities develop after completing treatment — something that SCIT itself may help prevent in monosensitized patients. If symptoms return after successfully completing SCIT, retreatment with an accelerated build-up schedule is an option; previously treated patients typically respond faster to a second course.
Related Articles
How Long Do Allergy Shots Take? Trial vs Reality | Curex
How long do allergy shots take to work? Trials show 12-month benefit, but only 23% complete 3 years. Real-world vs clinical data guide.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.